The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday — breaching a key psychological level.Bondsread more
The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Delta warned travelers that a technical problem could delay flights on Wednesday.Airlinesread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
Evercore ISI analyst Mark Schoenebaum was just named Institutional Investor's top sell-side analyst for large, mid and small cap stocks in the health care sector.
Overall, Schoenebaum remains bullish on the sector and is not worried about the recent weakness. Instead, he attributed the selloff to a simple "repositioning" from growth oriented, generalist portfolios.
"I call them biotourists," Schoenebaum told CNBC's "Power Lunch" on Wednesday. "These are the same investors who threw in the towel and returned to the sector after avoiding it for years."
Schoenebaum's favorite biotech stock is Gilead Science which develops treatments for cardiovascular, liver, respiratory and HIV/AIDs. He maintains a price target of $115 on the stock, in part because of what he calls their "fantastic" management team.
BioMarin Pharmaceuticals, which develops products to treat for serious burns and muscular dystrophy, is another favorite, in anticipation of a possible FDA approval later this year.
Year to date, BioMarin is up 44.5 percent, and outperformed the broader market by nearly 50 percent. Schoenebaum projects an additional ten percent climb for the stock.
Long-term, he's bullish on Biogen, which makes therapies for people living with neurological, autoimmune and hematologic disorders.
"It makes a lot of sense here. The upside-downside ratio is 5:1 over a two year period."
Schoenebaum thinks both stocks will return a minimum ten percent by the first quarter of 2016.
Evercore ISI expects to receive or intends to seek compensation for investment banking services from AbbVie within the next three months
Neither Schoenebaum, his family nor Evercore ISI have conflicts with Pfizer, BioMarin or Gilead Science.
CNBC's Michael Bloom contributed to this article